München (ots) - - Neue Folgen mit und über Deutschlands wahrscheinlich bekannteste Glamour-Familie ...
Viroblock SA receives First Round of Equity Funding
Plan-les-Ouates (ots) - Viroblock SA, a start-up dedicated to developing and commercializing a new generation of antiviral products, today announced that it has completed its first round of equity funding led by private investor Peter Pfister, Fongit Seed Invest SA, and Initiative Capital Romandie SA.
Viroblock also announced that the newly appointed Board of Directors will consist of Peter Pfister (Chairman), former CFO of Adecco; Igor Fisch, CEO of Selexis SA; Daniel Fustier, former Global Vice President of Covance and former head of Covance CLS SA in Geneva; Donald Wallach, founder and former professor at Harvard Medical School and Gian-Luigi Berini, an experienced hi-tech entrepreneur and board member of Fongit Seed Invest. Georges Haas, former Worldwide Head of Pharmaceutical Research and Preclinical Development at Ciba-Geigy has joined the scientific advisory board.
"We are delighted to have both experienced business people and accomplished scientists help us build the company. We are now excited to start the validation of our outstanding in vitro results in pre-clinical studies", said Thierry Pelet, CEO of Viroblock.
Viroblock is dedicated to developing and commercializing a new generation of antiviral products with a novel mechanism of action against enveloped viruses. Enveloped viruses represent more than 60 % of all existing viruses and include major human pathogens such as human and avian influenzas, the hepatitis B and C viruses and the AIDS virus.
Viroblock's unique proprietary products and technologies open very promising opportunities in a number of prophylactic and therapeutic applications.
Viroblock was founded in October 2005 by Donald Wallach, a scientist and academic now residing in Geneva with past tenure at the Harvard Medical School and Tufts University, and a pioneer in the research of liposome systems. The W. A. de Vigier Foundation nominated Viroblock as one of the 10 best technology projects of the year 2006, and the Selection Committee of the Swiss Tech Tour 2007 rated Viroblock as one of the top technology companies in Switzerland. Viroblock is based at the incubator FONGIT in Plan-les-Ouates, Geneva.
ots Originaltext: Viroblock SA Internet:
Thierry Pelet, CEO